[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-tumors-andor-solid-tumors-including\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-tumors-andor-solid-tumors-including":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100625277",false,"NCT07420543","Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach","FLUO-LB","Inclusion Criteria:\n\n* Inclusion Criteria (Glioblastoma Patients):\n* Patient aged 18 years or older\n* Diagnosis of supratentorial glioblastoma at its first occurrence (Grade 4, WHO 2021), confirmed through histological analysis, in a brain area that is accessible for surgical removal.\n* Ability of the patient to give informed consent.\n* Suitability for surgery with fluorescence guidance using 5-ALA.\n\nInclusion Criteria (Other Brain Tumors):\n\n* Patient aged 18 years or older\n* Ability of the patient to give informed consent.\n* Suitability for surgery with fluorescence guidance using 5-ALA.\n\nExclusion Criteria:\n\nExclusion Criteria (Glioblastoma Patients):\n\n* Presence of other systemic tumors.\n* Known allergic sensitivity or contraindications to gadolinium.\n* Contraindications to MRI, such as the presence of non-compatible implanted devices.\n* Significantly compromised renal function (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²), and\u002For patients undergoing dialysis.\n* Conditions that contraindicate surgery with fluorescence guidance using 5-ALA.\n\nExclusion Criteria (Other Brain Tumors):\n\n* Patients suffering from systemic tumors (besides the primary of the brain metastasis).\n* Individuals with known allergies or adverse reactions to gadolinium.\n* Individuals with contraindications for MRI, including those with implants not compatible with the procedure.\n* Individuals with significantly reduced kidney function (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²), or those undergoing dialysis.","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","Glioblastoma (GBM) is the most common and lethal primary brain tumor. Identifying blood biomarkers that reflect the tumor's status is a major unmet need for optimal clinical management. 5-ALA (5-Aminolevulinic Acid) administration leads to the accumulation of fluorescent Protoporphyrin IX (PpIX) in GBM cells, allowing identification during surgery. This project aims to leverage 5-ALA induced fluorescence to maximize the informational power of plasma liquid biopsy as a tool for diagnosis, post-treatment follow-up, and as a prognostic tool in patients with GBM.",[23,24,25,26],"Brain Tumors and\u002For Solid Tumors Including","Glioblastoma","Glioblastoma (GBM)","Glioblastoma - Category",[25,24,28,29,30,31,32],"Liquid Biopsy","GBM","5-ALA","Protoporphyrin IX (PpIX)","Fluorescence","RECRUITING","2026-02-11",{"date":36,"type":37},"2026-02-19","ACTUAL",{"date":39,"type":37},"2017-01-18",{"date":41,"type":19},"2027-05",{"name":43,"class":44},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","OTHER",""]